Pharmaceutical manufacturers of 3 3 diindolylmethane

Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad, deep-scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred Contract Development and Manufacturing Organization (CDMO) partner for personalized medicines, blockbuster drugs and consumer health brand extensions. Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply over 80 billion doses of nearly 8,000 products annually. Its rapidly growing expert workforce exceeds 18,000, including more than 3,000 scientists and technicians. Headquartered in Somerset, New Jersey, Catalent, Inc. (NYSE:CTLT), is in S&P 500® company, and generated nearly $5 billion in revenue in its 2022 fiscal year.

Korea Otsuka Pharmaceutical represents the Korean branch of the esteemed global pharmaceutical firm Otsuka Pharmaceutical. Despite being a division of a multinational pharmaceutical corporation, Korea Otsuka Pharmaceutical has established an independent operational base in South Korea and has contributed to the advancement of the pharmaceutical industry in Korea by reinvesting the earnings from pharmaceutical product sales into production equipment and clinical research.